Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

SPA agreement for pivotal phase III study of picoplatin in SCLC

Jan. 4, 2007

U.K. clearance for clinical study of Reolysin with docetaxel in advanced cancers

Jan. 4, 2007

Exelixis and Genentech sign agreement for MEK inhibitor XL-518

Jan. 4, 2007

Shandong Luye acquires cancer drug CMNa

Jan. 4, 2007

Enrollment open in phase II study of PX-12 for advanced pancreatic cancer

Jan. 3, 2007

Lorus Therapeutics reviews Q2 developments

Jan. 3, 2007

Tumor responses in phase II study of CA4P, paclitaxel and carboplatin

Jan. 3, 2007

Partial responses in pancreatic cancer study of glufosfamide plus gemcitabine

Jan. 3, 2007

Bioequivalence study of ANX-530 cleared to begin

Jan. 3, 2007

SKI-606 active in chronic myelogenous leukemia in phase I study

Jan. 3, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...